CA2123593C - Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale - Google Patents

Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale Download PDF

Info

Publication number
CA2123593C
CA2123593C CA002123593A CA2123593A CA2123593C CA 2123593 C CA2123593 C CA 2123593C CA 002123593 A CA002123593 A CA 002123593A CA 2123593 A CA2123593 A CA 2123593A CA 2123593 C CA2123593 C CA 2123593C
Authority
CA
Canada
Prior art keywords
tnf
tnfr
pro
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002123593A
Other languages
English (en)
Other versions
CA2123593A1 (fr
Inventor
Craig A. Smith
Cindy A. Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2123593(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of CA2123593A1 publication Critical patent/CA2123593A1/fr
Application granted granted Critical
Publication of CA2123593C publication Critical patent/CA2123593C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Procédé de traitement de maladies inflammatoires dépendantes du TNF chez un mammifère, consistant à administrer un antagoniste du TNF, tel qu'un récepteur de TNF soluble.
CA002123593A 1992-09-15 1993-09-14 Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale Expired - Lifetime CA2123593C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
US07/946,236 1992-09-15
PCT/US1993/008666 WO1994006476A1 (fr) 1992-09-15 1993-09-14 Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf

Publications (2)

Publication Number Publication Date
CA2123593A1 CA2123593A1 (fr) 1994-03-31
CA2123593C true CA2123593C (fr) 2000-03-14

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002123593A Expired - Lifetime CA2123593C (fr) 1992-09-15 1993-09-14 Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale

Country Status (8)

Country Link
EP (1) EP0620739A4 (fr)
JP (1) JPH07504203A (fr)
KR (1) KR100232688B1 (fr)
AU (1) AU670125B2 (fr)
CA (1) CA2123593C (fr)
NO (1) NO941780L (fr)
NZ (1) NZ256293A (fr)
WO (1) WO1994006476A1 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
ATE242322T1 (de) * 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
AU4658596A (en) * 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
DK0839046T3 (da) * 1995-07-14 2002-02-18 Applied Research Systems TNF-receptor og steroidhormon i en kombinationsterapi
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0910413A2 (fr) * 1996-05-08 1999-04-28 F. Hoffmann-La Roche Ag TRAITEMENT DE L'ASTHME PAR TNFR-Ig
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998024463A2 (fr) * 1996-12-06 1998-06-11 Amgen Inc. Therapie combinatoire utilisant une proteine de liaison du facteur de necrose tumorale (tnf) dans le traitement de maladies induites par le tnf
EP1352656A3 (fr) * 1996-12-06 2004-02-04 Amgen Inc. Thérapie combinatoire utilisant une protèine de liaison du facteur de nécrose tumorale (TNF) dans le traitement de maladies induites par le TNF
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0980258A1 (fr) * 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
WO1999003998A1 (fr) * 1997-07-17 1999-01-28 The Regents Of The University Of Michigan Procedes et compositions servant a reduire une tumeur
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE372126T1 (de) * 1998-11-05 2007-09-15 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (fr) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
WO2000059530A1 (fr) * 1999-04-02 2000-10-12 Immunex Corporation Utilisation d'un recepteur du facteur de necrose tumorale soluble dans le traitement de l'insuffisance cardiaque
EP1939300A1 (fr) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
DK1180159T3 (da) * 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
JP2003505427A (ja) * 1999-07-21 2003-02-12 オメロス コーポレイション 疼痛、炎症および軟骨分解の抑制のための溶液および方法
WO2001010908A1 (fr) 1999-08-04 2001-02-15 Amgen Inc. Ntr3, membre de la famille de supergenes recepteurs du tnf
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004009776A2 (fr) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Traitement de troubles en relation avec le tnf$g(a)
EP1575513A4 (fr) * 2002-08-16 2007-04-04 Wyeth Corp Compositions et methodes de traitement de troubles associes au recepteur rage
JP2006500927A (ja) * 2002-09-13 2006-01-12 ザ・ユニバーシティ・オブ・クイーンズランド コドン翻訳効率に基づく遺伝子発現系
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
JP4980048B2 (ja) * 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
NZ595225A (en) 2005-05-16 2013-05-31 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CN103336129A (zh) 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2008051306A1 (fr) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Récepteurs de tnf solubles et leur utilisation pour le traitement de maladies
WO2007109686A2 (fr) 2006-03-20 2007-09-27 University Of Pittsburgh Immunomodulation de conditions inflammatoires en utilisant la protéine 1 apparentée à la follistatine et des agents se liant à celle-ci
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
EP2666479A3 (fr) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de l'arthrite rhumatoïde juvénile
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
MX2008016335A (es) 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
SI2061803T2 (sl) 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2008025747A1 (fr) * 2006-08-28 2008-03-06 Ares Trading S.A. Procédé de purification de protéines fc-hybrides
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101600450A (zh) 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
WO2008150491A2 (fr) 2007-05-31 2008-12-11 Abbott Laboratories Biomarqueurs prédictifs de la réactivité aux inhibiteurs tnfα dans des troubles auto-immuns
WO2008154543A2 (fr) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Procédés de traitement de l'arthrite idiopathique juvénile
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
EP2072527A1 (fr) 2007-12-21 2009-06-24 Altonabiotec AG Procédé et système pour fournir des services de communications sur un terminal mobile, et terminal mobile
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
JP2012506694A (ja) * 2008-08-12 2012-03-22 アヴェストハゲン リミテッド 発現ベクターおよびその方法
US20110251099A1 (en) 2008-12-30 2011-10-13 Sudha Visvanathan SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
WO2010127146A1 (fr) 2009-04-29 2010-11-04 Abbott Biotechnology Ltd Dispositif d'injection automatique
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP2013512674A (ja) 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
US20110150891A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of Treating Interstitial Cystitis
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
JP5809242B2 (ja) 2010-04-21 2015-11-10 アッヴィ バイオテクノロジー リミテッド 治療薬の制御送達のための装着型自動注入装置
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
EP2575884B1 (fr) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Utilisations et compositions pour le traitement de l'hidrosadénite (hs)
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
WO2012019099A2 (fr) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Protéine 1 analogue à la follistatine utilisable en tant que biomarqueur des troubles inflammatoires
RU2727040C2 (ru) 2011-01-24 2020-07-17 Эббви Байотекнолоджи Лтд. Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
CA2829773A1 (fr) 2011-03-18 2012-09-27 Abbvie Inc. Systemes, dispositifs et procedes pour assembler des dispositifs a injection automatique et des sous-ensembles leur correspondant
MX2013011263A (es) 2011-03-29 2014-03-27 Abbvie Inc Despliegue de cubierta mejorado en dispositivos de inyeccion automaticos.
ES2605817T3 (es) 2011-04-21 2017-03-16 Abbvie Inc. Dispositivo de inyección automático portátil
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2718328A4 (fr) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions et procédés pour augmenter la demi-vie sérique
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
BR112014009146A8 (pt) 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
KR101525919B1 (ko) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체
SI2895188T1 (en) 2012-09-11 2018-05-31 Coherus Biosciences, Inc. CORRECTED QUALITY ETHANERCEPT WITH HIGH QUALITY AND EXCELLENT EXPERIENCE
CA2944605C (fr) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Procedes de traitement du psoriasis des ongles et du cuir chevelu
WO2015198320A1 (fr) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Procédés de purification d'anticorps
CA2970577A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
EP3440113A1 (fr) 2016-04-08 2019-02-13 Gilead Sciences, Inc. Compositions et méthodes de traitement du cancer, de maladies inflammatoires et de maladies autoimmunes
EP3257866A1 (fr) 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
CN110430801B (zh) 2016-12-14 2024-04-30 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN112654350A (zh) 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
SG11202101674QA (en) 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
WO2022123293A1 (fr) 2020-12-09 2022-06-16 에이치케이이노엔 주식회사 ANTICORPS ANTI-OX40L, ANTICORPS BISPÉCIFIQUE ANTI-OX40L/ANTI-TNFα ET LEURS UTILISATIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1991003553A1 (fr) * 1989-09-05 1991-03-21 Immunex Corporation RECEPTEURS DES FACTEURS NECROSE TUMORALE α et $g(b)
ES2145744T5 (es) * 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
CA2145192A1 (fr) * 1992-09-22 1994-03-31 Gail Underiner Nouveaux composes renfermant de l'epoxyde

Also Published As

Publication number Publication date
EP0620739A4 (en) 1997-01-15
NZ256293A (en) 1997-06-24
JPH07504203A (ja) 1995-05-11
AU4920993A (en) 1994-04-12
AU670125B2 (en) 1996-07-04
EP0620739A1 (fr) 1994-10-26
CA2123593A1 (fr) 1994-03-31
WO1994006476A1 (fr) 1994-03-31
NO941780L (no) 1994-07-15
KR100232688B1 (ko) 1999-12-01
NO941780D0 (no) 1994-05-11

Similar Documents

Publication Publication Date Title
CA2123593C (fr) Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU630497B2 (en) Tumor necrosis factor-alpha and -beta receptors
USRE36755E (en) DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) Fusion proteins comprising tumor necrosis factor receptor
US5712155A (en) DNA encoding tumor necrosis factor-α and -β receptors
EP0670730B1 (fr) Proteine de fusion comprenant deux recepteurs du facteur de necrose tumorale
AU646695B2 (en) Isolated viral protein cytokine antagonists
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
US7700318B2 (en) Chimeric polypeptide and use thereof
US20050042228A1 (en) Method and pharmaceutical composition for the treatment of immune disorders
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists
NZ280051A (en) Tnf-r dimers (tumour necrosis factor - receptor), dna coding for same and vectors including the dna

Legal Events

Date Code Title Description
EEER Examination request